Türeci Ö - Search Results

1

Serum Troponin I Assessments in 5- to 30-Year-Olds After BNT162b2 Vaccination.

Albertson TE, Hansen C, Bihari S, Gayed J, Xu X, Simón-Campos JA, Dever ME, Cardona JF, Mitha E, Baker JB, Keep G, Oladipupo I, Mensa FJ, Feng Y, Ma H, Koury K, Mather S, Ianos CA, Anderson AS, Türeci Ö, Şahin U, Gruber WC, Gurtman A, Sabharwal C, Kitchin N; C4591031, C4591007 Clinical Trial Groups. Albertson TE, et al. Among authors: tureci o. Infect Dis Ther. 2024 Apr;13(4):699-714. doi: 10.1007/s40121-024-00927-0. Epub 2024 Mar 15. Infect Dis Ther. 2024. PMID: 38489117 Free PMC article.

2

Identification of tumor-associated autoantigens with SEREX.

Türeci O, Usener D, Schneider S, Sahin U. Türeci O, et al. Methods Mol Med. 2005;109:137-54. doi: 10.1385/1-59259-862-5:137. Methods Mol Med. 2005. PMID: 15585919

3

The human X chromosome is enriched for germline genes expressed in premeiotic germ cells of both sexes.

Koslowski M, Sahin U, Huber C, Türeci O. Koslowski M, et al. Among authors: tureci o. Hum Mol Genet. 2006 Aug 1;15(15):2392-9. doi: 10.1093/hmg/ddl163. Epub 2006 Jun 29. Hum Mol Genet. 2006. PMID: 16809397

4

In silico strategy for detection of target candidates for antibody therapy of solid tumors.

Helftenbein G, Koslowski M, Dhaene K, Seitz G, Sahin U, Türeci O. Helftenbein G, et al. Among authors: tureci o. Gene. 2008 May 15;414(1-2):76-84. doi: 10.1016/j.gene.2008.02.009. Epub 2008 Feb 19. Gene. 2008. PMID: 18358640

5

Tumor vaccination using messenger RNA: prospects of a future therapy.

Kreiter S, Diken M, Selmi A, Türeci Ö, Sahin U. Kreiter S, et al. Among authors: tureci o. Curr Opin Immunol. 2011 Jun;23(3):399-406. doi: 10.1016/j.coi.2011.03.007. Epub 2011 Apr 13. Curr Opin Immunol. 2011. PMID: 21497074 Review.

6

Targeting the tumor mutanome for personalized vaccination therapy.

Kreiter S, Castle JC, Türeci O, Sahin U. Kreiter S, et al. Among authors: tureci o. Oncoimmunology. 2012 Aug 1;1(5):768-769. doi: 10.4161/onci.19727. Oncoimmunology. 2012. PMID: 22934277 Free PMC article.

7

Antitumor vaccination with synthetic mRNA: strategies for in vitro and in vivo preclinical studies.

Diken M, Kreiter S, Selmi A, Türeci O, Sahin U. Diken M, et al. Among authors: tureci o. Methods Mol Biol. 2013;969:235-46. doi: 10.1007/978-1-62703-260-5_15. Methods Mol Biol. 2013. PMID: 23296938 Review.

8

Claudin 18.2 is a target for IMAB362 antibody in pancreatic neoplasms.

Wöll S, Schlitter AM, Dhaene K, Roller M, Esposito I, Sahin U, Türeci Ö. Wöll S, et al. Among authors: tureci o. Int J Cancer. 2014 Feb 1;134(3):731-9. doi: 10.1002/ijc.28400. Epub 2013 Sep 16. Int J Cancer. 2014. PMID: 23900716 Free article.

9

Antigen identification using SEREX.

Sahin U, Türeci O. Sahin U, et al. Among authors: tureci o. Methods Mol Biol. 2013;1061:59-77. doi: 10.1007/978-1-62703-589-7_3. Methods Mol Biol. 2013. PMID: 23963930

10

mRNA-based therapeutics--developing a new class of drugs.

Sahin U, Karikó K, Türeci Ö. Sahin U, et al. Among authors: tureci o. Nat Rev Drug Discov. 2014 Oct;13(10):759-80. doi: 10.1038/nrd4278. Epub 2014 Sep 19. Nat Rev Drug Discov. 2014. PMID: 25233993 Review.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

192 results

Search Page